Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization

Journal of Microbiology, Immunology and Infection

Volumn 48, Issue 2, 2015, Pages 183-189

  Lin, Hsiao Ju ^a   Hung, Yuan Pin ^a,c   Liu, Hsiu Chuan ^a   Lee, Jen Chieh ^b   Lee, Chih I ^a   Wu, Yi Hui ^d   Tsai, Pei Jane ^b   Ko, Wen Chien ^b  

^a Tainan Hospital   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

Author keywords

Clostridium difficile colonization; Clostridium difficile infection; Piperacillin tazobactam; Proton pump inhibitors; Risk factors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; FOSFOMYCIN; GLYCOPEPTIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; STEROID; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BODY MASS; BODY WEIGHT; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; DIABETES MELLITUS; DIARRHEA; FECES ANALYSIS; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; NOSE FEEDING; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TOXIGENIC CLOSTRIDIUM DIFFICILE COLONIZATION; ADULT; ANALOGS AND DERIVATIVES; CLOSTRIDIUM INFECTIONS; FECES; GENETICS; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PUBLIC HOSPITAL; RISK FACTOR; TAIWAN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIABETES COMPLICATIONS; DIARRHEA; FECES; FEMALE; HOSPITALIZATION; HOSPITALS, DISTRICT; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS; TAIWAN;

EID: 84924585696     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2013.08.003     Document Type: Article

References (36)

1. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359:1932-1940.
2. Dial S., Delaney J.A., Barkun A.N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
3. Loo V.G., Bourgault A.M., Poirier L., Lamothe F., Michaud S., Turgeon N., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011, 365:1693-1703.
4. Jayatilaka S., Shakov R., Eddi R., Bakaj G., Baddoura W.J., DeBari V.A. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007, 37:241-247.
5. Kim M.J., Kim B.S., Kwon J.W., Ahn S.E., Lee S.S., Park H.C., et al. Risk factors for the development of Clostridium difficile colitis in a surgical ward. J Korean Surg Soc 2012, 83:14-20.
6. Chung C.H., Wu C.J., Lee H.C., Yan J.J., Chang C.M., Lee N.Y., et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J Microbiol Immunol Infect 2010, 43:119-125.
7. Lee Y.C., Wang J.T., Chen A.C., Sheng W.H., Chang S.C., Chen Y.C. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect 2012, 45:287-295.
8. Hung Y.P., Tsai P.J., Hung K.H., Liu H.C., Lee C.I., Lin H.J., et al. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS One 2012, 7:e42415.
9. Riggs M.M., Sethi A.K., Zabarsky T.F., Eckstein E.C., Jump R.L., Donskey C.J. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992-998.
10. Faires M.C., Pearl D.L., Ciccotelli W.A., Straus K., Zinken G., Berke O., et al. A prospective study to examine the epidemiology of methicillin-resistant Staphylococcus aureus and Clostridium difficile contamination in the general environment of three community hospitals in southern Ontario, Canada. BMC Infect Dis 2012, 12:290.
11. Kato H., Kita H., Karasawa T., Maegawa T., Koino Y., Takakuwa H., et al. Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J Med Microbiol 2001, 50:720-727.
12. Delaney J.A., Dial S., Barkun A., Suissa S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007, 13:761-763.
13. Settle C.D., Wilcox M.H., Fawley W.N., Corrado O.J., Hawkey P.M. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998, 12:1217-1223.
14. Ackermann G., Tang Y.J., Jang S.S., Silva J., Rodloff A.C., Cohen S.H. Isolation of Clostridium innocuum from cases of recurrent diarrhea in patients with prior Clostridium difficile associated diarrhea. Diagn Microbiol Infect Dis 2001, 40:103-106.
15. Satomura H., Odaka I., Sakai C., Kato H. Antibiotic-associated diarrhea due to Clostridium perfringens. Kansenshogaku Zasshi 2009, 83:549-552.
16. Hunley T.E., Spring M.D., Peters T.R., Weikert D.R., Jabs K. Clostridium septicum myonecrosis complicating diarrhea-associated hemolytic uremic syndrome. Pediatr Nephrol 2008, 23:1171-1175.
17. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
18. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
19. Shah K., Pass L.A., Cox M., Lanham M., Arnold F.W. Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. J Trauma Acute Care Surg 2012, 72:691-695.
20. Brown K.A., Khanafer N., Daneman N., Fisman D.N. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013, 57:2326-2332.
21. Janarthanan S., Ditah I., Adler D.G., Ehrinpreis M.N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107:1001-1010.
22. Wilcox M.H., Freeman J., Fawley W., MacKinlay S., Brown A., Donaldson K., et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004, 54:168-172.
23. Alston W.K., Ahern J.W. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother 2004, 53:549-550.
24. Mendez M.N., Gibbs L., Jacobs R.A., McCulloch C.E., Winston L., Guglielmo B.J. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 2006, 26:61-67.
25. Stevens V., Dumyati G., Fine L.S., Fisher S.G., van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
26. Pultz N.J., Donskey C.J. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005, 49:3529-3532.
27. Kwok C.S., Arthur A.K., Anibueze C.I., Singh S., Cavallazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012, 107:1011-1019.
28. Jump R.L., Pultz M.J., Donskey C.J. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?. Antimicrob Agents Chemother 2007, 51:2883-2887.
29. Zedtwitz-Liebenstein K., Wenisch C., Patruta S., Parschalk B., Daxbock F., Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002, 30:1118-1122.
30. Vesteinsdottir I., Gudlaugsdottir S., Einarsdottir R., Kalaitzakis E., Sigurdardottir O., Bjornsson E.S. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 2012, 31:2601-2610.
31. Cho S.M., Lee J.J., Yoon H.J. Clinical risk factors for Clostridium difficile-associated diseases. Braz J Infect Dis 2012, 16:256-261.
32. Aseeri M., Schroeder T., Kramer J., Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008, 103:2308-2313.
33. Dial S., Alrasadi K., Manoukian C., Huang A., Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33-38.
34. Wong-McClure R.A., Guevara-Rodríguez M., Abarca-Gómez L., Solano-Chinchilla A., Marchena-Picado M., O'Shea M., et al. Clostridium difficile outbreak in Costa Rica: control actions and associated factors. Rev Panam Salud Publica 2012, 32:413-418.
35. Wenisch J.M., Schmid D., Kuo H.W., Simons E., Allerberger F., Michl V., et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis 2012, 31:1923-1930.
36. Shakov R., Salazar R.S., Kagunye S.K., Baddoura W.J., DeBari V.A. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 2011, 39:194-198.